⚠️ JAN 12 – FEB 6 CYBERATTACK: ALL ORDERS REFUNDED • DO NOT PURCHASE UNTIL FURTHER NOTICE • CONTACT support@anubis.estate FOR REFUND STATUS
ApprovedVitamin

011503 DAPSONE 6% / NIACINAMIDE 2% / SPIRONOLACTONE 5%

Formula Pending

Molecular Mass
N/A
CAS Registry
N/A
Risk Class
LOW
Last Audit
Jan 1, 2024

Research Abstract

Vitamin medication

011503 DAPSONE 6% / NIACINAMIDE 2% / SPIRONOLACTONE 5% is a vitamin asset inside marketed initiatives, optimized for therapeutic and clinical research.

The dossier currently sits in approved with a low risk rating, meaning it is cleared for baseline monitoring protocols.

Supply records cite CAS N/A with updates logged 2024-01-01.

Acquisition Protocol

Authorized research personnel may request deployment of this compound for laboratory analysis.

Initiate TransferReturn to Index

Primary Vectors

TherapeuticClinical Research

Nomenclature

011503 DAPSONE 6% / NIACINAMIDE 2% / SPIRONOLACTONE 5%

Reference Material

  1. [1] Anubis Compound Registry • CAS N/A
  2. [2] Operations Pulse • Marketed
  3. [3] Risk Governance Ledger • LOW clearance for 011503-DAPSONE-6-NIACINAMIDE-2-SPIRONOLACTONE-5